
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc. has demonstrated solid revenue growth within its Retail segment, reporting $255 million in sales for the quarter, which reflects an 8.1% quarter-over-quarter and a 7.8% year-over-year increase. The company is on track to achieve an expected free cash flow (FCF) of $205 million in 2025, significantly increasing from $109 million in 2024, as it has maintained positive FCF for four consecutive quarters. Furthermore, the gross and operating margins are expected to improve moderately, with targeted annual expansions of 25-50 basis points and 50-100 basis points, respectively, indicating a potential enhancement in overall profitability in the coming years.
Bears say
Diebold Nixdorf's stock outlook is negative due to several fundamental factors affecting its financial health, including technological missteps and an inability to innovate, which may hinder revenue growth and profitability. The company's Banking segment has experienced a decline in total gross margins, which were reported at 26.8%, reflecting a 70 basis point decrease quarter-over-quarter, indicating increasing competitive pressure and potential issues in demand for its products. Additionally, uncertainties such as tariff-related costs, supply chain disruptions, and volatility in foreign exchange rates further complicate the company's ability to maintain stable financial performance and meet its debt obligations.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares